Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
_256_384.jpg)
Cipla had earlier invested € 15 million in Ethris in 2022
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
Subscribe To Our Newsletter & Stay Updated
